TGFB1 and pulmonary fibrosis: On the other hand, Nanocyl increased only TGF-β release from fibroblasts [27], which has previously been used in vitro to stimulate the pro-inflammatory response [35,48,63] and in vivo to stimulate the development of pulmonary fibrosis [56,68].